Drugs that contain Tivozanib Hydrochloride
1. List of Fotivda drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7166722 | AVEO PHARMS | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
Nov, 2023
(5 months from now) | |
| US6821987 | AVEO PHARMS | Quinoline derivatives and quinazoline derivatives having azolyl group |
Apr, 2024
(10 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11504365 | AVEO PHARMS | NA |
Nov, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 10, 2026 |
NCE-1 date: 2025-03-10
Market Authorisation Date: 10 March, 2021
Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...
Dosage: CAPSULE;ORAL
FOTIVDA family patents
9
Japan
8
United States
4
European Union
3
Germany
3
Australia
3
Austria
2
Canada
2
Brazil
2
Denmark
2
Spain
2
Norway
1
Chile
1
Poland
1
Korea, Republic of
1
Hong Kong
1
Taiwan
1
China
1
Netherlands
1
Belgium
1
Mexico
1
New Zealand
1
EA
1
South Africa
1
Portugal
1
Russia
1
Israel
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic